Molecular Genetics of Schizophrenia - nonGAIN Sample (MGS_nonGAIN)

This study is part of the Molecular Genetics of Schizophrenia (MGS) genome wide association study (GWAS) of 3,972 cases
(2,686 EA and 1,286 AA) and 3,629 controls (2,656 EA and 973 AA) (analyzed sample remaining after quality control exclusions),
comprised of European ancestry (EA) and African American (AA) samples. We genotyped about half of the EA sample and almost all
of the AA sample under the auspices of the Genetic Association Information Network (GAIN) with the Affymetrix 6.0 platform at the
Broad Institute. The remainder of the included sample was also genotyped with the Affymetrix 6.0 platform at the Broad Institute,
and we refer to this component as the nonGAIN sample. Cases met criteria for schizophrenia (SCZ) or schizoaffective disorder
(SA) per the Diagnostic and Statistical Manual of Mental Disorders version IV (DSM-IV) for all three collections (SGI, MGS1,
and MGS2) comprising these cases. However, for the older SGI collection, codes for the secondary diagnoses refer to the older
DSM-III-R version. Controls were screened briefly and excluded if they endorsed a history of these illnesses.]]>
Lifetime Dimensions of Psychosis Scale (LDPS)FIGS- Relatives: (MGS2 Relatives Only)Family Interview for Genetic StudiesDIAGNOSTIC INTERVIEW FOR GENETIC STUDIES (DIGS) 2.0 Modified (MGS)Controls Questionnaire Administered On-Line by Knowledge Networks (KN)Control Clinical ProtocolsCases: Clinical ProtocolsMolecular Genetics of Schizophrenia II - Best Estimate Diagnosis Code SheetDEMOGRAPHICS, AMEDICAL HISTORY, BMODIFIED MINI-MENTAL STATUS EXAMINATION, COVERVIEW OF PSYCHIATRIC DISTURBANCE, EMAJOR DEPRESSION, FMANIA/HYPOMANIA, GDYSTHYMIA/DEPRESSIVE/HYPERTHYMIC PERSONALITY, HALCOHOL ABUSE AND DEPENDENCE, IDRUG ABUSE AND DEPENDENCE, JPSYCHOSIS, KCOMORBIDITY ASSESSMENT, NSUICIDAL BEHAVIOR, OGLOBAL ASSESSMENT SCALE, PSCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS (SANS), USCALE FOR THE ASSESSMENT OF POSITIVE SYMPTOMS (SAPS), VINTERVIEWER’S RELIABILITY ASSESSMENT, XNARRATIVE SUMMARY, YMEDICAL RECORDS INFORMATION, ZAPPENDIXPlease refer to the following documents for detailed information:
"Cases_Protocol.pdf" and
"Controls_Protocol.pdf". Briefly,
all subjects had to give informed consent, be at least 18 years old, and be able to communicate in English. Included cases
had a consensus best estimate final diagnosis of DSM-IV SCZ or SA. Cases were excluded if they had worse than mild mental
retardation, or if their psychotic illness was judged to be secondary to substance use or a neurological disorder. Some case
parents were included to make trios that were only used for quality control purposes (e.g., Mendelian checks of SNPs). Controls
were excluded if they did not deny all of the following psychosis screening questions: treatment for or diagnosis of schizophrenia or
schizoaffective disorder; treatment for or diagnosis of bipolar disorder or manic-depression; treatment for or diagnosis of
psychotic symptoms such as auditory hallucinations or persecutory delusions.]]>
Samples were collected under the following grants: NIMH Schizophrenia Genetics Initiative U01s: MH46276, MH46289, and MH46318; and
Molecular Genetics of Schizophrenia Part 1 (MGS1) and Part 2 (MGS2) R01s: MH67257, MH59588, MH59571, MH59565, MH59587, MH60870, MH60879,
MH59566, MH59586, and MH61675. Genotyping and analyses were funded under the MGS U01s: MH79469 and MH79470.]]>